Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Experimental MERS Coronavirus Vaccine Shows Promise

    By Global Biodefense StaffJuly 29, 2015
    Share
    Facebook LinkedIn Reddit Email

    National Institutes of Health scientists are reporting positive results from a two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS).

    The regimen prompted immune responses in mice and rhesus macaques, generating neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV.

    The findings suggest that the current approach, in which vaccine design is guided by an understanding of structure of viral components and their interactions with host cells, holds promise for developing a similar human MERS vaccine regimen.

    The research team was led by Barney S. Graham, M.D., Ph.D., Wing-Pui Kong, Ph.D., and colleagues at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center.

    Currently, no licensed vaccines are available for MERS, a disease that first appeared in 2012. An outbreak in the Republic of Korea that began in May has caused more than 180 confirmed infections, including 36 deaths, through July 15 as well as widespread social disruption.

    The investigators used structural information about a viral protein called the spike (S) glycoprotein, which MERS-CoV uses to enter cells, to design a number of experimental vaccines that they administered to mice in a two-step regimen involving an initial “priming” injection followed several weeks later by the same or a different “booster” vaccine.

    The three prime-boost regimens that elicited the most robust immune responses in mice were then tested in groups of macaques and were found to elicit similar immune system responses.

    A separate group of 18 macaques (12 vaccinated, six unvaccinated) were exposed to MERS-CoV 19 weeks after the vaccinated animals received the boost injection. Although macaques do not develop overt MERS disease, the researchers observed that unvaccinated animals experienced lung abnormalities indicative of pneumonia that were more profound and longer lasting than those seen in the vaccinated animals.

    The team is now working on refining the vaccine candidates and may eventually test a second-generation vaccine candidate in clinical trials.

    Read more: Evaluation of candidate vaccine approaches for MERS-CoV.

    Coronavirus Emerging Threats MERS-CoV Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleEnterovirus C105 Possibly Linked to Child Paralysis Outbreak
    Next Article 100 Percent Efficacy Shown for VSV-EBOV Ebola Vaccine

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    The Basics on the Nipah Virus Outbreak in India

    September 19, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy